Updated on 12 June 2013
Earlier this year, Indonesia had launched oral rotavirus vaccine candidate, RV3, a new vaccine developed through Indonesia-Australia research collaboration to reduce the burden of diarrheal disease. RV3 was developed in partnership with Australia's Murdoch Children's Research Institute (MCRI) and Indonesia's Universitas Gadjah Mada.
Diarrhea is the leading cause of death in children under five years of age in Indonesia, and 35 to 84 percent of the cases were found to be caused by rotavirus. RV3 is an effective and affordable vaccine, that can given orally to newborn babies, to provide the earliest possible protection.
Together with the Indonesian Ministry for Research and Technology, Australian Academy of Science, on behalf of the DIICCSRTE (Department of Industry, Innovation, Climate Change, Science, Research and Tertiary Education), has previously facilitated a number of bilateral events. These events included joint symposium on science and technology (2006); joint working group in science and innovation, research and technology (2007); workshop on human health including infectious diseases (2008), workshop on agriculture and food security (2009); and workshop on environmental science (2011).
Also, the Academy's Science by Doing team is assisting Indonesia to develop a pilot science curriculum unit for Indonesian secondary school students written in Bahasa Indonesia. If the pilot proves successful, it will be used as model for a full suite of units for Indonesia. The program is funded by the Australian government through AusAID and DIICCSRTE.